Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Nov 17:19:41-43.
doi: 10.1016/j.jdcr.2021.11.007. eCollection 2022 Jan.

Dupilumab-induced erythema nodosum

Danielle E Mustin  1 , Emily F Cole  2 , Travis W Blalock  2 , Merin E Kuruvilla  3 , Benjamin K Stoff  2 , Ron J Feldman  2
Affiliations
Case Reports

Dupilumab-induced erythema nodosum

Danielle E Mustin et al. JAAD Case Rep. .
No abstract available

Keywords: AD, atopic dermatitis; EN, erythema nodosum; IL, interleukin; adverse reaction; biologic treatment for asthma; dupilumab; erythema nodosum.

PubMed Disclaimer

Conflict of interest statement

None disclosed.

Figures

Fig 1
Fig 1
Clinical presentation. Erythematous nodules and plaques on the right lower extremity.
Fig 2
Fig 2
Punch biopsy from the lower leg. Septal fibrosis with a mixed granulomatous and lymphohistiocytic inflammatory infiltrate with scattered admixed eosinophils. (Original magnification: ×100.)
Fig 3
Fig 3
Clinical resolution. Resolution of nodules and plaques on the lower extremities 6 weeks after discontinuation of dupilumab therapy.
See this image and copyright information in PMC

References

    1. Regeneron Pharmaceuticals DUPIXENT (dupilumab) prescribing information. 2021. https://www.regeneron.com/downloads/dupixent_fpi.pdf
    1. Jo C.E., Finstad A., Georgakopoulos J.R., Piguet V., Yeung J., Drucker A.M. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339–1347. - PubMed
    1. Xiong X.F., Zhu M., Wu H.X., Fan L.L., Cheng D.Y. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108. - PMC - PubMed
    1. Wang Y., Jorizzo J. Difference in the rate of ocular adverse events with dupilumab between asthma and atopic dermatitis patients. Int J Dermatol. 2021;60(9):e382. - PubMed
    1. Dupin C., Belhadi D., Guilleminault L., et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Exp Allergy. 2020;50(7):789–798. - PubMed

Publication types